Meta-Analysis Shows Semaglutide Reduces Major Cardiovascular Events in Type 2 Diabetes Patients
A systematic review and meta-analysis demonstrates that semaglutide significantly reduces major adverse cardiovascular events in adults with type 2 diabetes, with particular benefits for nonfatal myocardial infarction and stroke.
A systematic review and meta-analysis of randomized controlled trials found that semaglutide significantly reduces major adverse cardiovascular events in adults with type 2 diabetes. The analysis included trials with at least 500 participants and minimum 12-month follow-up that reported MACE as a primary or major secondary endpoint, defined as the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke.
For subcutaneous semaglutide formulations, the pooled hazard ratio for MACE was 0.84 (95% CI: 0.76–0.93; I2 = 0%) across 2 trials involving 12,833 participants. Oral semaglutide demonstrated a hazard ratio of 0.74 (95% CI: 0.58–0.95) in 1 trial with 3,297 participants.
The analysis revealed specific benefits for individual cardiovascular outcomes. Nonfatal myocardial infarction risk was reduced with a hazard ratio of 0.74 (95% CI: 0.63–0.87; I2 = 0%). Nonfatal stroke showed even greater risk reduction with a hazard ratio of 0.61 (95% CI: 0.47–0.80; I2 = 23%). Cardiovascular death showed a hazard ratio of 0.88 (95% CI: 0.76–1.02; I2 = 0%).
All-cause mortality was reduced across studies with a hazard ratio of 0.85 (95% CI: 0.75–0.96; I2 = 0%).
Sensitivity analyses confirmed the robustness of findings. Excluding SUSTAIN-6 yielded HR = 0.85 (95% CI: 0.77–0.93). Excluding PIONEER-6 resulted in HR = 0.83 (95% CI: 0.76–0.92). Excluding SOUL produced HR = 0.76 (95% CI: 0.61–0.95).
Semaglutide 1.0mg weekly (Ozempic) achieves HbA1c reduction of 1.4-1.8% from baseline. Semaglutide 2.4mg weekly results in 14.9% total body weight loss at 68 weeks, with 64.9% achieving ≥10% weight loss.
For patients with established cardiovascular disease, semaglutide provides 20-26% reduction in cardiovascular death, nonfatal MI, or nonfatal stroke (HR 0.74-0.80). Semaglutide has dedicated kidney outcomes data showing beneficial effects on CKD progression. Both medications require no dose adjustment across all CKD stages, including eGFR <30 mL/min/1.73 m². Both medications have neutral effect on heart failure hospitalization risk.
The trials included adult patients (≥18 years) with type 2 diabetes in randomized, placebo-controlled designs comparing semaglutide (oral or subcutaneous formulation) versus placebo.